---
authors:
- Ohri, Smriti
- Summa, Maria
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/39283860/
file_path: 2024/09/resmetirom-rezdiffra-for-the-treatment-of-noncirrhotic-nonal.md
issue: '3'
keywords:
- Liver Cirrhosis
- Treatment Outcome
- Non-alcoholic Fatty Liver Disease
- Humans
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Non-alcoholic Fatty Liver Disease
- Liver Cirrhosis
- Treatment Outcome
original_format: PubMed
pages: 313-314
patient_population: Adults
peer_reviewed: true
pmid: '39283860'
processed_date: '2025-07-30'
publication_date: '2024-09-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Resmetirom (Rezdiffra) for the Treatment of Noncirrhotic Nonalcoholic Steatohepatitis
  With Moderate to Advanced Fibrosis.
topics:
- Family Medicine
volume: '110'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '39283860'
  title: Resmetirom (Rezdiffra) for the Treatment of Noncirrhotic Nonalcoholic Steatohepatitis
    With Moderate to Advanced Fibrosis.
  authors:
  - last_name: Ohri
    fore_name: Smriti
    initials: S
    affiliation: Oregon Health and Science University, Portland, Oregon.
  - last_name: Summa
    fore_name: Maria
    initials: M
    affiliation: UCONN Health, Farmington, Connecticut.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '110'
    issue: '3'
  publication_info:
    year: '2024'
    month: 09
    full_date: '2024-09-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Non-alcoholic Fatty Liver Disease
    major_topic: true
    qualifiers:
    - qualifier: diagnosis
      major_topic: false
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Liver Cirrhosis
    major_topic: true
    qualifiers:
    - qualifier: complications
      major_topic: false
  - descriptor: Treatment Outcome
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '39283860'
  title: Resmetirom (Rezdiffra) for the Treatment of Noncirrhotic Nonalcoholic Steatohepatitis
    With Moderate to Advanced Fibrosis.
  authors:
  - name: Ohri S
    authtype: Author
    clusterid: ''
  - name: Summa M
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Sep
- pmid: '39155764'
  title: Budget impact of resmetirom for the treatment of adults with non-cirrhotic
    non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis
    (consistent with stages F2 to F3 fibrosis).
  authors:
  - name: Fishman J
    authtype: Author
    clusterid: ''
  - name: Kim Y
    authtype: Author
    clusterid: ''
  - name: Paris√© H
    authtype: Author
    clusterid: ''
  - name: Bercaw E
    authtype: Author
    clusterid: ''
  - name: Smith Z
    authtype: Author
    clusterid: ''
  source: J Med Econ
  pubdate: 2024 Jan-Dec
- pmid: '39292422'
  title: Estimation of the Eligible Population For Resmetirom Among Adults in the
    United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver
    Fibrosis.
  authors:
  - name: Fishman J
    authtype: Author
    clusterid: ''
  - name: Kim Y
    authtype: Author
    clusterid: ''
  - name: Charlton MR
    authtype: Author
    clusterid: ''
  - name: Smith ZJ
    authtype: Author
    clusterid: ''
  - name: O'Connell T
    authtype: Author
    clusterid: ''
  - name: Bercaw EM
    authtype: Author
    clusterid: ''
  source: Adv Ther
  pubdate: 2024 Nov
- pmid: '38771485'
  title: 'Resmetirom: First Approval.'
  authors:
  - name: Keam SJ
    authtype: Author
    clusterid: ''
  source: Drugs
  pubdate: 2024 Jun
- pmid: '38772519'
  title: 'Resmetirom''s approval: Highlighting the need for comprehensive approaches
    in NASH therapeutics.'
  authors:
  - name: Alshehade SA
    authtype: Author
    clusterid: ''
  source: Clin Res Hepatol Gastroenterol
  pubdate: 2024 Aug
---

# Resmetirom (Rezdiffra) for the Treatment of Noncirrhotic Nonalcoholic Steatohepatitis With Moderate to Advanced Fibrosis.

**Authors:** Ohri, Smriti, Summa, Maria

**Published in:** American family physician | Vol. 110, No. 3 | 2024-09-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/39283860/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Treatment Outcome

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/39283860/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
